Weems v. Hy-Vee Food Stores, Inc.
526 N.W.2d 571 (1994)
Premium Feature
Subscribe to Lexplug to listen to the Case Podcast.
Rule of Law:
An original tortfeasor is liable for additional bodily harm resulting from normal medical efforts to treat the initial injury, and such treatment will not be considered a superseding cause even if it results in rare or unforeseeable complications, so long as the treatment itself was a normal and foreseeable response to the injury.
Facts:
- Leonard Weems was a customer at a Drug Town store owned by Hy-Vee Stores, Inc.
- Weems slipped and fell on a wet floor inside the store.
- As a result of the fall, Weems developed lingering lower-back pain.
- Approximately eighteen months later, Weems sought medical treatment for his persistent back pain from Dr. Arnold Delbridge, an orthopedic surgeon.
- Dr. Delbridge administered an epidural block, a standard spinal steroid injection, to alleviate the pain.
- As a result of the epidural procedure, Weems contracted an infection that led to spinal meningitis.
- Evidence presented showed that an epidural block is a common treatment for chronic back pain and that spinal meningitis is a known, though very rare, risk associated with the procedure.
Procedural Posture:
- Leonard Weems and his wife sued Hy-Vee Stores, Inc. in an Iowa trial court for damages arising from his slip-and-fall injury.
- The case proceeded to a jury trial.
- During the trial, Hy-Vee requested a jury instruction on the doctrine of superseding cause, which the trial court refused to give.
- The jury found Hy-Vee 60% at fault and awarded damages to Weems and his wife.
- Hy-Vee filed a post-trial motion for a new trial, arguing the court erred by failing to provide the superseding cause instruction.
- The trial court denied the motion for a new trial.
- Hy-Vee (appellant) appealed the trial court's judgment to the Iowa Court of Appeals (intermediate appellate court).
Premium Content
Subscribe to Lexplug to view the complete brief
You're viewing a preview with Rule of Law, Facts, and Procedural Posture
Issue:
Does a rare but known adverse side effect of a common and accepted medical procedure, administered to treat an injury caused by a defendant's negligence, constitute a superseding cause that relieves the defendant of liability for the harm resulting from that side effect?
Opinions:
Majority - Cady, Judge.
No. A rare but known adverse side effect of a common and accepted medical procedure does not constitute a superseding cause. An original tortfeasor is liable for harm resulting from subsequent medical treatment required by the initial injury, as such treatment is a normal and foreseeable consequence of the negligence. The foreseeability analysis focuses on the intervention itself (medical treatment), not the specific, rare harm that results from it. Since seeking medical care for a back injury is a normal consequence of a fall, and the epidural was an accepted treatment for such an injury, Hy-Vee's negligence created the risk that Weems would be exposed to the hazards of medical treatment. The fact that the resulting spinal meningitis was a rare complication is immaterial, as it was a known risk of a foreseeable medical intervention. Therefore, the medical treatment was not an extraordinary act that could sever the causal chain.
Analysis:
This case reinforces the established tort principle that a tortfeasor is responsible for all foreseeable consequences of their negligence, including the risks inherent in subsequent medical treatment. The court's analysis clarifies that the 'foreseeability' test for a superseding cause applies to the intervening act itself (i.e., the need for medical care), not the specific outcome or rarity of a complication. This decision strengthens the position of plaintiffs by making it difficult for original tortfeasors to shift blame for medical complications, thereby placing the risk of such unfortunate but foreseeable events on the party whose negligence created the need for treatment in the first place.
Unlock the full brief for Weems v. Hy-Vee Food Stores, Inc.